AzTrials
AzTrials

Acute Ischaemic StrokeNCT06379464

Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study

An observational study of Acute Ischaemic Stroke and Depression, run by Zhujiang Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques. Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Acute Ischaemic Stroke, Depression
How many people
320 participants
Where
1 siteChina
Study dates
1 Sep 2023to 30 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: 1. Patients with acute ischaemic stroke; 2. Depressed patients

Who may be able to join

  • Age range from 18 to 90 years old;
  • Patients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke;
  • Sign the informed consent form, provide relevant medical history information and provide blood, urine and stool samples.
  • Age range from 18 to 90 years old;
  • Patients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders;
  • Sign the informed consent form, provide relevant medical history information and provide oral swabs, blood, urine and stool samples.

Who cannot join

  • Serious systemic diseases including malignancies;
  • Alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal value or severe liver disease;
  • Creatinine >1.5 times the upper limit of normal or severe nephropathy;
  • A long-term history of drinking, drug taking and chemical poisoning. A long-term history of drinking refers to a history of more than 5 years, equivalent to alcohol >40g/d for men and 20g/d for women, or a history of heavy drinking within 2 weeks, equivalent to alcohol >80g/d;
  • Those with previous history of intestinal tumor, irritable bowel syndrome or inflammatory bowel disease or diagnosed in Hospital;
  • Unable to retain the required samples.
Show all 13Show fewer
  • Depressed patients:
  • Serious systemic diseases including malignancies;
  • Alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal value or severe liver disease;
  • Creatinine >1.5 times the upper limit of normal or severe nephropathy;
  • A long-term history of drinking, drug taking and chemical poisoning. A long-term history of drinking refers to a history of more than 5 years, equivalent to alcohol >40g/d for men and 20g/d for women, or a history of heavy drinking within 2 weeks, equivalent to alcohol >80g/d;
  • Those with previous history of intestinal tumor, irritable bowel syndrome or inflammatory bowel disease or diagnosed in Hospital;
  • Unable to retain the required samples.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Zhujiang Hospital of Southern Medical University

    Guanzhou, Guangdong, 510145

    Hongwei Zhou, Professor, 186 8848 9622, hzhou@smu.edu.cn

    Recruiting

Other trials in China

About this study

Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques.

Read the detailed description

With environmental changes, population aging, and the accelerated pace of social life, cerebrovascular diseases and mental illnesses have gradually become a major disease burden in China. Stroke is the second leading cause of death globally, as well as the leading cause of death and disability in China. In recent years, the prevalence and incidence of stroke have increased significantly in our country. Global Burden of Disease 2017 reported a stroke incidence rate of 258 (95% CI, 234-284) per 100,000 person-years and a mortality rate of 88 (95% CI, 80-94) per 100,000 person-years. Depression is one of the most common psychiatric disorders, with a lifetime prevalence of 15-18%, a recurrence rate of approximately 80%, and a disease outcome that worsens with increasing age of onset. World Health Organization measurements show that the disease burden of depression accounts for 10% of the total burden of all types of illness and disability. Its pathogenesis is still unknown, treatment options are limited, and most patients suffer from recurrent or prolonged illness for life. The etiology and pathophysiological mechanisms of stroke and depression remain unknown, and objective and reliable biological diagnostic markers are lacking.

As research strategies focusing on the central nervous system have encountered difficulties, the field has begun to look to the periphery for new clues. With the advancement of multi-omics studies integrating genome, transcriptome, epigenome, proteome, and metabolomics, important roles of gut microbiota have been discovered to influence the function and structure of the nervous system by regulating metabolites, the immune system, and neurotransmitters, etc. Benakis et al. found that gut-derived IL17+γδ T cells migrate to the meninges and promote post-stroke injury. Clearance of gut microbiota induced changes in dendritic cell activity, increased Treg cells, and decreased IL17+γδ T cells, which in turn alleviated stroke injury. Therefore, T-lymphocytes dependent on intestinal immunity are strongly associated with stroke severity. Previous studies have shown that IL-17 produced by γδ T cells in the meninges is an important factor in inducing anxious behavior and IFN-γ is important in maintaining social willingness, whereas pro-inflammatory factors such as IL-1β, IL-6 and TNF-α produced by inflammatory responses are highly correlated with depression, so that T-cell immunity may be associated with depression. Stroke and depression present a similar pathogenesis and spectrum of disease traits. IL-17+γδ T cells have been shown to be involved in the mechanism of injury after ischemic stroke; high levels of IL-17 are associated with depression, which is a common comorbidity of diseases such as the above. This suggests that the relevant immune pathways represented by IL-17 and γδ T cells may be a common pathogenic mechanism for stroke and depression. Previous studies have also shown that both diseases exhibit enrichment of Enterobacteriaceae. The applicant's team's findings, published in Gut, reveal that ischemic stroke can trigger a disturbance of the gut microbiota characterized by an overproliferation of Enterobacteriaceae, and that the disturbed microbiota can further contribute to the progression of brain injury and is associated with poor stroke outcomes. The mechanism is that stroke-induced intestinal ischemia leads to an increase in nitrate concentration in the intestinal mucus layer, and Enterobacteriaceae, which can undergo nitrate respiration, overpopulate as a result. A systematic review published in Clinical Psychology Review summarized 26 studies, including 20 case-control studies, and found that the gut microbiota of patients with anxiety and depression exhibited an enrichment of pro-inflammatory bacteria such as Enterobacteriaceae. Thus, disorders of the gut microbiota characterized by Enterobacteriaceae are all associated with the above major brain diseases.

In summary, stroke and depression patients share common and respective unique characteristics of gut microbiota, metabolites, and immune factors. In this study, we intend to identify the key factors of intestinal bacteria and target novel biomarkers in stroke and depression through cross-sectional study of stroke and depression, using cutting-edge multi-omics technology.

Medical subject headings
Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06379464
Study groupRoleWhat they receive
Patients with acute ischaemic strokePatients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke.
Depressed patientsPatients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The severity of neurological damage in stroke patients

    The severity of neurological damage in stroke patient evaluated by National Institutes of Health Stroke Scale(NHISS), the scoring range is 0-42 points, with higher scores indicating more severe neurological damage.

    Measured: The evaluation will be conducted on the second day after admission

  2. The functional recovery outcomes after stroke

    The functional recovery outcomes after stroke evaluated by Modified Rankin Scale(mRS), the scoring range is 0-6 points, with higher scores indicating worse functional outcome.

    Measured: The evaluation will be conducted at 3 months after admission

  3. The severity of symptoms in patients with depression

    The severity of symptoms in patients with depression is evaluated by Hamilton Depression Scale(HAMD), the scoring range is 0-54 points, with higher scores indicating more severe depressive states.

    Measured: The evaluation will be conducted on the second day after admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Apr 2024
  2. Study start1 Sep 2023
  3. Primary completion30 Jun 2024 (estimated)
  4. Study completion30 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
320 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06379464
Sponsor's protocol ID
CALM2303
Status last verified
Aug 2023
First submitted
6 Apr 2024
Last updated
23 Apr 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Ischaemic Stroke and Depression, run by Zhujiang Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kaiyu XU (13590349187, 1500810165@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The severity of neurological damage in stroke patients (time frame: The evaluation will be conducted on the second day after admission). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in